Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma

Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma

The most common subtype of renal cell carcinoma is clear cell renal cell carcinoma (ccRCC). While localized ccRCC can be cured with surgery, metastatic disease has a poor prognosis. Recently, immunotherapy has emerged as a promising approach for advanced ccRCC. This review provides a comprehensive o...

Full description

Bibliographic Details
Main Authors:	Lingbin Meng, Katharine A. Collier, Peng Wang, Zihai Li, Paul Monk, Amir Mortazavi, Zhiwei Hu, Daniel Spakowicz, Linghua Zheng, Yuanquan Yang
Format:	Article
Language:	English
Published:	MDPI AG 2023-12-01
Series:	Cells
Subjects:	clear cell renal cell carcinoma immune checkpoint inhibitors immunotherapeutic combinations bispecific antibodies CAR T cells vaccines
Online Access:	https://www.mdpi.com/2073-4409/13/1/34

Similar Items

NK Cell-Based Immunotherapy in Colorectal Cancer
by: Mariella Della Chiesa, et al.
Published: (2022-06-01)

Recent developments in immunotherapy of acute myeloid leukemia
by: Felix S. Lichtenegger, et al.
Published: (2017-07-01)

Emerging technology trends in regulatory approvals of cancer immunotherapy drugs by the FDA and EMA
by: Maryam Monajati, et al.
Published: (2024-09-01)

In Vivo Secretion of Bispecific Antibodies Recruiting Lymphocytic Effector Cells
by: Luis Alvarez-Vallina, et al.
Published: (2013-06-01)

Immunotherapy Strategy for Systemic Autoimmune Diseases: Betting on CAR-T Cells and Antibodies
by: Vitaly Chasov, et al.
Published: (2024-02-01)

Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment
by: Rahul Navab, et al.
Published: (2025-01-01)

Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses
by: Antonio Tapia-Galisteo, et al.
Published: (2024-12-01)

Editorial: Dendritic Cell-Based Immunotherapy in Solid and Haematologic Tumors
by: Riccardo Dolcetti, et al.
Published: (2020-03-01)

Current Immunotherapy Approaches in Non-Hodgkin Lymphomas
by: Robert Pytlik, et al.
Published: (2020-11-01)

Understanding the Spatial Topology of Artificial Immunological Synapses Assembled in T Cell-Redirecting Strategies: A Major Issue in Cancer Immunotherapy
by: Pedro Roda-Navarro, et al.
Published: (2020-01-01)

CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma
by: Massimiliano Gambella, et al.
Published: (2022-02-01)

Emerging Trends in Immunotherapy for Cancer
by: Alok K. Mishra, et al.
Published: (2022-09-01)

Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies
by: Olivier Nolan-Stevaux, et al.
Published: (2024-11-01)

Current status of immunotherapy for non-small cell lung cancer
by: Tao Yang, et al.
Published: (2022-10-01)

Editorial: New insights into innate immune cell-based immunotherapies in cancer
by: Anne Caignard, et al.
Published: (2024-04-01)

The Role of T Cell Immunotherapy in Acute Myeloid Leukemia
by: Fang Hao, et al.
Published: (2021-12-01)

CAR-T cells and BiTEs in solid tumors: challenges and perspectives
by: Julien Edeline, et al.
Published: (2021-04-01)

Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
by: Joanie Del Bano, et al.
Published: (2015-12-01)

CARS as a Prognosis Factor in Clear Cell Renal Cell Carcinoma and Its Association with Tumor Immunity
by: Meng Q, et al.
Published: (2021-07-01)

Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures
by: Deep Shah, et al.
Published: (2023-05-01)

Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy
by: Zong Sheng Guo, et al.
Published: (2020-07-01)

Real-world data of second-line immunotherapy in metastatic clear cell renal cell carcinoma: A retrospective study
by: Waseem Abbas, et al.
Published: (2021-01-01)

Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm
by: Alana L. Keller, et al.
Published: (2022-06-01)

Depleting Tumor Cells Expressing Immune Checkpoint Ligands—A New Approach to Combat Cancer
by: Fabrizio Marcucci, et al.
Published: (2021-04-01)

Editorial: Bispecific Antibodies for T-Cell Based Immunotherapy
by: Brian H. Santich, et al.
Published: (2020-12-01)

Evaluation of Anti-CAR Linker mAbs for CAR T Monitoring after BiTEs/bsAbs and CAR T-Cell Pretreatment
by: Anja Grahnert, et al.
Published: (2024-07-01)

Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review
by: Joseph Sassine, et al.
Published: (2025-01-01)

Emerging Immunotherapies for Advanced Non-Small-Cell Lung Cancer
by: Emily Wolf, et al.
Published: (2025-01-01)

Immunotherapy and Tyrosine Kinase Inhibitor as a Bridge to Surgery for Clear Cell Renal Cell Carcinoma Metastases to the Thyroid: A Case Report and Literature Review
by: Robert Bränström, et al.
Published: (2024-10-01)

Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment
by: Amanda Rosewell Shaw, et al.
Published: (2018-09-01)

Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
by: Johannes Sam, et al.
Published: (2020-11-01)

Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
by: Johannes Sam, et al.
Published: (2021-02-01)

BCMA-targeted immunotherapy for multiple myeloma
by: Bo Yu, et al.
Published: (2020-09-01)

CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure
by: Ana Carolina Caballero, et al.
Published: (2022-07-01)

Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
by: Neeraj Jain, et al.
Published: (2023-08-01)

Beyond checkpoint inhibition – Immunotherapeutical strategies in combination with radiation
by: F. Eckert, et al.
Published: (2017-02-01)

Regulatory T cells as immunotherapy
by: Benjamin David Singer, et al.
Published: (2014-02-01)

Recommendations for the effective use of T-cell–redirecting therapies: a Canadian consensus statement
by: Guido Lancman, et al.
Published: (2024-11-01)

Editorial: Targeting regulatory cells in cancer: old and new approaches in immunotherapy
by: Luigi Cari, et al.
Published: (2024-07-01)

Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment
by: Baijin Xia, et al.
Published: (2023-09-01)